PR94654

Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets

OSAKA, Japan, Feb. 24, 2022 /PRNewswire=KYODO JBN/ --

    Global pharma major, Lupin Limited (Lupin) announced today changes to its

executive team with Dr. Fabrice Egros assuming responsibilities for Global

Corporate Development as President, Corporate Development and Growth Markets.

Dr. Egros takes over the Corporate Development role from Alan Butcher departing

from the Company on February 28, 2022. Dr. Egros will lead the development and

execution of the Company's inorganic growth strategy, including mergers and

acquisitions, business development, in-licensing arrangements, and related

matters. He will continue to lead business in LATAM and Asia regions in this

new role.

    "We are very pleased to announce Fabrice taking over responsibilities for

Corporate Development in addition to the Growth Markets business. With

Fabrice's leadership and demonstrated success in growing Lupin's business

through both organic and inorganic initiatives, we are well positioned to

deliver on our growth aspirations.  We thank Alan for his contribution to our

organization and wish him well for the future," said Vinita Gupta, CEO, Lupin.

    For the past over six years, Dr. Egros has played an integral role in

Lupin, leading businesses across both Growth and Developed markets. His

extensive cross-border experience as well as successful experience with

acquisitions, divestitures, joint ventures and partnerships will be an asset to

Lupin in this new role.

    About Lupin

    Lupin is an innovation-led transnational pharmaceutical company

headquartered in Mumbai, India. The Company develops and commercializes a wide

range of branded and generic formulations, biotechnology products, and APIs in

over 100 markets in the U.S., India, South Africa, and across the Asia Pacific

(APAC), Latin America (LATAM), Europe, and the Middle East regions.

    The Company enjoys a leadership position in the cardiovascular,

anti-diabetic, and respiratory segments and has a significant presence in the

anti-infective, gastro-intestinal (GI), central nervous system (CNS), and

women's health areas. Lupin is the third-largest pharmaceutical company in the

U.S. by prescriptions. The company invested 9.6% of its revenue in research and

development in FY21.

    Lupin has 15 manufacturing sites, 7 research centers, more than 20,000

professionals working globally, and has been consistently recognized as a

'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

    Please visit www.lupin.com for more information.

    Follow us on Twitter: https://twitter.com/LupinGlobal|LinkedIn:

https://www.linkedin.com/company/lupin

    Facebook: http://www.facebook.com/LupinWorld/

    For further information:

    Shweta Munjal

    Vice President & Global Head – Corporate Communications

    Email: shwetamunjal@lupin.com

    Logo:

https://mma.prnewswire.com/media/1158525/lupin_pharmaceuticals_Logo.jpg

    Source: Lupin Pharmaceuticals Inc.